Critique of the two-fold measure of prediction success for ratios: Application for the assessment of drug-drug interactions

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 170-173

  Guest, Eleanor J ^a   Aarons, Leon ^a   Houston, J Brian ^a   Rostami Hodjegan, Amin ^a,b   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; ATORVASTATIN; AZITHROMYCIN; CARBAMAZEPINE; CHLORZOXAZONE; CIMETIDINE; FLUCONAZOLE; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; GATIFLOXACIN; MIDAZOLAM; NITRENDIPINE; PARECOXIB; RANITIDINE; RIFAMPICIN; SIMVASTATIN; TERBINAFINE; VALDECOXIB;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; DRUG INTERACTION; INTERMETHOD COMPARISON; PHARMACOLOGICAL PARAMETERS; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL;

ALGORITHMS; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DRUG INTERACTIONS; MIDAZOLAM; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH DESIGN; UNCERTAINTY;

EID: 79251479419     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036103     Document Type: Article

References (22)

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
2. Brown HS, Galetin A, Hallifax D, and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
3. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, Seo PR, Suh K, Thompson CL, and Yu LX (2008) Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J 10:148-156.
4. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
5. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
6. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
7. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
8. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190. (Pubitemid 41058254)
9. Guest EJ, Rowland Yeo K, Rostami-Hodjegan A, Tucker GT, Houston B, and Galetin A (2010) Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72-87.
10. Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
11. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304.
12. Hyland R, Dickins M, Collins C, Jones H, and Jones B (2008) Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66:498-507.
13. Kharasch ED, Jubert C, Senn T, Bowdle TA, and Thummel KE (1999) Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 39:664-669.
14. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, and Ensign D (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410-426.
15. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
16. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today 1:441-448.
17. Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, Dobrinska MR, Endrenyi L, Fairweather W, Gillespie W, Gonzalez MA, et al. (1996) Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res 13:1590-1594.
18. Teitelbaum Z, Lave T, Freijer J, and Cohen AF (2010) Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans. Clin Pharmacokinet 49:619-632.
19. Tothfalusi L, Endrenyi L, and Arieta AG (2009) Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 48:725-743.
20. United States Food and Drug Administration (2003) Bioavailability and Bioequivalence Studies for Orally Administered Products - General Considerations. United States Food and Drug Administration: Draft Guidance for Industry, Washington, DC.
21. Wang YH (2010) Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38:1094-1104.
22. Zhao P, Zhang L, Lesko LJ, and Huang SM (2010) Utility of physiologically-based pharmacokinetic modeling and simulation in drug development and challenges in regulatory reviews. Clin Pharmacol Ther 87:S68-S95.